Drug intelligence / Profile preview

PF-06413367

Development stage: Phase 1
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-06413367 is an investigational drug candidate developed by Pfizer that has been evaluated in combination with PF-05402536 as part of a vaccine immunotherapy approach for smoking cessation. It was tested in healthy adult smokers to assess its safety, tolerability, and immunogenicity. Specific mechanism of action or target information is not publicly detailed, but both drugs (PF-06413367 and PF-05402536) are referred to as "smoking vaccines," suggesting a potential immune-based modality aimed at nicotine or a related target[3][4][7]. The drug has completed Phase 1 clinical studies, and no further advanced clinical development has been publicly reported.

Other names: anti-nicotine vaccinenicotine vaccine

Beyond the preview

Go deeper on PF-06413367.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06413367.

Explore the full profile